$642 Million is the total value of GREAT POINT PARTNERS LLC's 30 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZFGN | Sell | ZAFGEN INC | $39,645,000 | +10.7% | 3,391,385 | -3.1% | 6.18% | +24.5% |
| KURA | Sell | KURA ONCOLOGY INC | $37,084,000 | -22.4% | 2,119,106 | -19.3% | 5.78% | -12.8% |
| PTCT | Sell | PTC THERAPEUTICS INC | $33,721,000 | -36.3% | 717,458 | -54.3% | 5.26% | -28.3% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $24,831,000 | -18.7% | 1,196,098 | -40.2% | 3.87% | -8.6% |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $23,094,000 | -3.6% | 4,030,268 | -15.7% | 3.60% | +8.4% |
| ONCE | Sell | SPARK THERAPEUTICS INC | $21,446,000 | -48.2% | 393,147 | -21.4% | 3.34% | -41.7% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $10,109,000 | +2.1% | 982,449 | -33.3% | 1.58% | +14.8% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $834,000 | -87.6% | 490,843 | -78.5% | 0.13% | -86.1% |
| CTIC | Sell | CTI BIOPHARMA CORP | $46,000 | -99.4% | 21,441 | -98.6% | 0.01% | -99.3% |
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -2,500 | -100.0% | -0.00% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -804,483 | -100.0% | -0.06% | – |
| CGEN | Exit | COMPUGEN LTDord | $0 | – | -759,494 | -100.0% | -0.35% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -1,056,825 | -100.0% | -0.45% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INCcall | $0 | – | -145,900 | -100.0% | -0.58% | – |
| AMRN | Exit | AMARIN CORP PLCcall | $0 | – | -1,596,200 | -100.0% | -0.68% | – |
| XLRN | Exit | ACCELERON PHARMA INCcall | $0 | – | -107,900 | -100.0% | -0.73% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -2,988,716 | -100.0% | -1.17% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INCput | $0 | – | -200,000 | -100.0% | -1.25% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -3,407,840 | -100.0% | -1.34% | – |
| EXEL | Exit | EXELIXIS INCcall | $0 | – | -500,000 | -100.0% | -1.49% | – |
| Exit | CORSICANTO II DESIGNATED ACTnote | $0 | – | -10,000,000 | -100.0% | -1.51% | – | |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -302,000 | -100.0% | -1.82% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -110,506 | -100.0% | -1.90% | – |
| NVCR | Exit | NOVOCURE LTD | $0 | – | -713,998 | -100.0% | -3.10% | – |
| XLRN | Exit | ACCELERON PHARMA INCput | $0 | – | -552,300 | -100.0% | -3.71% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INCcall | $0 | – | -602,200 | -100.0% | -3.77% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -770,400 | -100.0% | -4.83% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.